



CASE STUDY

YPrime IRT in Action: Rapid COVID-19 Vaccine Study Implementation

YPrime

The Challenge

During the height of the COVID-19 pandemic, a sponsor approached YPrime with an urgent need to implement an IRT system for a Phase 2/3 randomized, blinded, placebo-controlled vaccine study. With over 8,000 subjects across nearly 50 sites, the study demanded rapid deployment to support an urgent public health initiative while maintaining the highest standards of quality and compliance.

The Requirements:

- Full-featured IRT system implementation
- Complex randomization and blinding capabilities
- Complete drug accountability and supply management across multiple sites
- Seamless integration with existing clinical systems
- Regulatory compliance and data integrity assurance

The Solution

YPrime provided comprehensive IRT expertise and rapid deployment capabilities to meet the sponsor's urgent timeline. Through a deep understanding of vaccine trial requirements and accelerated development processes, YPrime delivered a complete IRT solution in less than four weeks from contract signing to go-live, providing:

- Full-featured IRT for randomization and blinding in a two-visit vaccine study design
- Treatment arm assignment and placebo controls management
- Complete drug supply management and accountability
- Site inventory tracking and management
- Automated shipment triggers and supply optimization
- Real-time reporting and study metrics



The Results

YPrime's ability to rapidly deploy a robust IRT solution proved instrumental in advancing this critical Phase 2/3 COVID-19 vaccine study. The sponsor successfully launched their study within four weeks while maintaining full regulatory compliance—meeting accelerated development timelines. YPrime's configurable platform and deep expertise in vaccine trials helped the study team effectively manage drug supply and patient randomization across all study sites.

This highly successful implementation showcased YPrime's ability to deliver complex IRT solutions within unprecedented timelines. This rapid deployment enabled the sponsor to maintain the highest standards of clinical trial management and regulatory compliance while advancing their crucial research. The successful execution of this large-scale study, managing over 8,000 participants across nearly 50 sites, demonstrated YPrime's expertise in supporting high-priority clinical research initiatives.



YPrime's expertise in delivering high-quality IRT solutions is evident in the successful execution of this large-scale study, with 8,000 participants across nearly 50 sites. Not only did we drive exceptional results, but we also supported a seamless launch in under four weeks—demonstrating our unwavering commitment to speed, flexibility, and certainty.

About YPrime

YPrime simplifies clinical trials with eCOA, IRT, and eConsent solutions that combine speed, flexibility, and quality. Our intuitive eCOA platform enhances patient compliance, streamlines site workflows, integrates with connected devices, and provides real-time dashboards for sponsors. With a pre-validated platform, we reduce eCOA startup times by 47%, faster than industry norms. Trusted by top pharma leaders and emerging biotech companies alike, YPrime offers ~50% faster IRT startup and quality metrics 55% above industry standards. Serving 100+ countries and 250+ languages, we are your partner in solving for certainty. Visit www.yprime.com or email marketing@yprime.com.

YPrime